Compare Trade Desk Inc (TTD) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trade Desk Inc vs GeneDx Holdings Corp — how do they compare? Trade Desk Inc trades at $12.11 (market cap $5.83B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Trade Desk Inc is far larger — about 2.9× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Trade Desk Inc for 72 Days and GeneDx Holdings Corp for 19 Days on average.
| TTD | WGS | |
|---|---|---|
Market Cap | $5.83B | $2.02B |
Volume | 15,864,392 | 734,640 |
Sector | Media | Health |
52-Week High | $54.13 | $167.51 |
52-Week Low | $11.92 | $34.51 |
Typical Hold Time | 72 Days | 19 Days |
Enterprise Value | $4.78B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The Trade Desk (TTD) trades at $12.08, down 0.08% with a bearish technical signal. The company shows strong fundamentals with 2025 revenue of $2.90B and net income of $443.30M, though 2026 guidance indicates slowing growth. Valuation metrics appear attractive with P/E of 0.15 and P/S of 0.02. Recent news highlights competitive pressures from Amazon and Alphabet while the company navigates workforce reductions.
Investment outlook remains cautious despite attractive valuations. The stock faces headwinds from slowing revenue growth and intense competition, but maintains leadership in programmatic advertising. Analyst consensus suggests 22% upside to $14.72 target, though mixed ratings reflect uncertainty about near-term catalysts.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
